Cargando…

Potential Tumor Suppressor Role of Polo-like Kinase 5 in Cancer

SIMPLE SUMMARY: Cancer is a complex disease and the underlying molecular mechanisms driving cancer initiation and progression is crucial for the development of effective approaches for cancer management. Exploring the molecular landscape of cancer can shed light on novel biomarkers, therapeutic targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Shengqin, Ndiaye, Mary Ann, Guzmán-Pérez, Glorimar, Baus, Rebecca Michael, Huang, Wei, Patankar, Manish Suresh, Ahmad, Nihal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669931/ https://www.ncbi.nlm.nih.gov/pubmed/38001717 http://dx.doi.org/10.3390/cancers15225457

Ejemplares similares

The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
por: de Cárcer, Guillermo
Publicado: (2019)

Polo-like kinase in trypanosomes: an odd member out of the Polo family
por: Kurasawa, Yasuhiro, et al.
Publicado: (2020)

Role for polo-like kinase 4 in mediation of cytokinesis
por: Press, Michael F., et al.
Publicado: (2019)

Roles of Polo-like kinase 3 in suppressing tumor angiogenesis
por: Xu, Dazhong, et al.
Publicado: (2012)

Putting a bit into the polo-box domain of polo-like kinase 1
por: Park, Jung-Eun, et al.
Publicado: (2015)

The balance of Polo-like kinase 1 in tumorigenesis
por: Lu, Lin-Yu, et al.
Publicado: (2009)

The CINs of Polo-Like Kinase 1 in Cancer
por: Cunningham, Chelsea E., et al.
Publicado: (2020)

Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer
por: Coley, Helen M., et al.
Publicado: (2012)

PLK1 inhibition-based combination therapies for cancer management
por: Su, Shengqin, et al.
Publicado: (2021)

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2017)

Polo-like kinase-1 in DNA damage response
por: Hyun, Sun-Yi, et al.
Publicado: (2014)

Polo-like kinase 1 as target for cancer therapy
por: Weiß, Lily, et al.
Publicado: (2012)

Playing POLO-like kinase in NRAS mutant melanoma
por: Chen, Hsin-Yi, et al.
Publicado: (2015)

Polo-Like Kinase 2: From Principle to Practice
por: Zhang, Chuanyong, et al.
Publicado: (2022)

Polo-like kinase 1 promotes pulmonary hypertension
por: Chen, Rongrong, et al.
Publicado: (2023)

Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1
por: Yun, Sang-Moon, et al.
Publicado: (2009)

A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening
por: Abdelfatah, Sara, et al.
Publicado: (2018)

The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis
por: Fu, Zheng, et al.
Publicado: (2017)

Exploring the Binding Nature of Pyrrolidine Pocket-Dependent Interactions in the Polo-Box Domain of Polo-Like Kinase 1
por: Murugan, Ravichandran N., et al.
Publicado: (2013)

Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain
por: Chen, Yunyu, et al.
Publicado: (2016)

Polo-Like Kinase Controls Vertebrate Spindle Elongation and Cytokinesis
por: Brennan, Ian M., et al.
Publicado: (2007)

Polo-like kinase 4: the odd one out of the family
por: Sillibourne, James E, et al.
Publicado: (2010)

Enhanced polo-like kinase 1 expression in myelodysplastic syndromes
por: Min, Kyoung Il, et al.
Publicado: (2019)

Therapeutic inhibition of polo‐like kinases in anaplastic thyroid cancer
por: Lin, Shu‐Fu, et al.
Publicado: (2021)

Chemical Probe for Imaging of Polo-like Kinase 4 and Centrioles
por: Salim, Aleksandar, et al.
Publicado: (2023)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor
por: Alimova, Irina, et al.
Publicado: (2017)

MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1
por: Liu, Jing, et al.
Publicado: (2012)

Design and Synthesis of a Cell-Permeable, Drug-Like Small Molecule Inhibitor Targeting the Polo-Box Domain of Polo-Like Kinase 1
por: Srinivasrao, Ganipisetti, et al.
Publicado: (2014)

Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe
por: Li, Jingjing, et al.
Publicado: (2015)

Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors
por: Jadhav, Mrunal, et al.
Publicado: (2021)

Polo-like kinase is required for Golgi and bilobe biogenesis in Trypanosoma brucei
por: de Graffenried, Christopher L., et al.
Publicado: (2008)

Autophosphorylation of Polo-like Kinase 4 and Its Role in Centriole Duplication
por: Sillibourne, James E., et al.
Publicado: (2010)

NFκB regulates expression of Polo-like kinase 4
por: Ledoux, Adeline C, et al.
Publicado: (2013)

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
por: Gjertsen, B T, et al.
Publicado: (2015)

Linear Regression QSAR Models for Polo-Like Kinase-1 Inhibitors
por: Duchowicz, Pablo R.
Publicado: (2018)

Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases
por: Hennenberg, Martin, et al.
Publicado: (2018)

A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas
por: Gatz, Susanne A., et al.
Publicado: (2019)

High Expression of Polo-Like Kinase 1 Is Associated with Early Development of Hepatocellular Carcinoma
por: Sun, Wei, et al.
Publicado: (2014)

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate
por: Abdelfatah, Sara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i6c7m10oh9kik1ugvp9s11deuf